Surgical stage in the era of molecular profiling of endometrial
cancer

J 2026

Surgical stage in the era of molecular profiling of endometrial cancer

KASIUS, J. C.; W. KILDAL; S. W. VREDE; H. A. ASKAUTRUD; M. PRADHAN et al.

Základní údaje

Originální název

Surgical stage in the era of molecular profiling of endometrial cancer

Autoři

Vydání

European Journal of Cancer, London, ELSEVIER, 2026, 0959-8049

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.100 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Endometrial cancer; Tumor stage; Tumor spread; Molecular classification; Survival

Štítky

14110240, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2026 13:35, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Molecular classification has reshaped risk stratification in endometrial cancer (EC), yet the relevance of tumor spread within molecular subgroups has not been reported so far. Material and methods: This multicenter retrospective study included 2056 EC patients treated between 1994 and 2018 across 11 European centers. All histopathological subtypes and FIGO stages were included. Tumors were classified into four molecular subgroups: POLE-mutated (POLEmut), mismatch repair deficient (MMRd), no specific molecular profile (NSMP), and TP53/p53 abnormal (p53abn). Clinical and pathological data were extracted from existing cohort databases. Results: Patients were diagnosed with FIGO stage I (69 %), II (9 %), III (16 %), and IV (6 %), and classified into: POLEmut (8 %), MMRd (28 %), NSMP (44 %), and p53abn (21 %). The overall 5-year cancer-specific death (CSD) and recurrence rates were 16.5 % (95 % CI, 14.9 %-18.2 %) and 23.8 % (95 % CI, 22.0 %-25.7 %), respectively. In multivariable analysis cancer-specific survival (CSS) was independently associated with molecular subtype, FIGO stage, age, histopathological type, grade, lymphovascular space invasion, adjuvant therapy, residual tumor, and lymphadenectomy. FIGO stage was significantly associated with CSD also in within each molecular subgroup (p < 0.001). Patients with tumors confined to the uterus had the most favourable prognosis. Lymph node metastases significantly decreased CSS in POLEmut, MMRd, and p53abn groups. Within FIGO stage IV, molecular subtype was not significantly related to outcome. Discussion: Surgical stage remains a strong prognostic factor across molecular subtypes and should be considered alongside molecular classification when tailoring adjuvant treatment in EC.

Citovat

KASIUS, J. C.; W. KILDAL; S. W. VREDE; H. A. ASKAUTRUD; M. PRADHAN; A. M. VAN ALTENA; K.-A.R. TOBIN; K. KNOLL; C. REIJNEN; S. REIMANN; G. DACKUS; L. VLATKOVIC; J. HUVILA; M. STEINLECHNER; V. TUBITA; A. GIL-MORENO; M. P. L. M. SNIJDERS; M. C. VOS; T. S. HVEEM; J. ASBERGER; A. G. ZEIMET; X. MATIAS-GUIU; K. LINDEMANN; Vít WEINBERGER; N. C. M. VISSER; G. B. KRISTENSEN; F. AMANT; J. M. A. PIJNENBORG a A. KLEPPE. Surgical stage in the era of molecular profiling of endometrial cancer. European Journal of Cancer. London: ELSEVIER, 2026, roč. 233, January 2026, s. 1-10. ISSN 0959-8049. Dostupné z: https://doi.org/10.1016/j.ejca.2025.116164.

@article{2547628,
   author = {Kasius, J. C. and Kildal, W. and Vrede, S. W. and Askautrud, H. A. and Pradhan, M. and Van Altena, A. M. and Tobin, K.andA.R. and Knoll, K. and Reijnen, C. and Reimann, S. and Dackus, G. and Vlatkovic, L. and Huvila, J. and Steinlechner, M. and Tubita, V. and GilandMoreno, A. and Snijders, M. P. L. M. and Vos, M. C. and Hveem, T. S. and Asberger, J. and Zeimet, A. G. and MatiasandGuiu, X. and Lindemann, K. and Weinberger, Vít and Visser, N. C. M. and Kristensen, G. B. and Amant, F. and Pijnenborg, J. M. A. and Kleppe, A.},
   article_location = {London},
   article_number = {January 2026},
   doi = {https://doi.org/10.1016/j.ejca.2025.116164},
   keywords = {Endometrial cancer; Tumor stage; Tumor spread; Molecular classification; Survival},
   language = {eng},
   issn = {0959-8049},
   journal = {European Journal of Cancer},
   title = {Surgical stage in the era of molecular profiling of endometrial cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S0959804925010500},
   volume = {233},
   year = {2026}
}

TY  - JOUR
ID  - 2547628
AU  - Kasius, J. C. - Kildal, W. - Vrede, S. W. - Askautrud, H. A. - Pradhan, M. - Van Altena, A. M. - Tobin, K.-A.R. - Knoll, K. - Reijnen, C. - Reimann, S. - Dackus, G. - Vlatkovic, L. - Huvila, J. - Steinlechner, M. - Tubita, V. - Gil-Moreno, A. - Snijders, M. P. L. M. - Vos, M. C. - Hveem, T. S. - Asberger, J. - Zeimet, A. G. - Matias-Guiu, X. - Lindemann, K. - Weinberger, Vít - Visser, N. C. M. - Kristensen, G. B. - Amant, F. - Pijnenborg, J. M. A. - Kleppe, A.
PY  - 2026
TI  - Surgical stage in the era of molecular profiling of endometrial cancer
JF  - European Journal of Cancer
VL  - 233
IS  - January 2026
SP  - 1-10
EP  - 1-10
PB  - ELSEVIER
SN  - 09598049
KW  - Endometrial cancer
KW  - Tumor stage
KW  - Tumor spread
KW  - Molecular classification
KW  - Survival
UR  - https://www.sciencedirect.com/science/article/pii/S0959804925010500
N2  - Introduction: Molecular classification has reshaped risk stratification in endometrial cancer (EC), yet the relevance of tumor spread within molecular subgroups has not been reported so far. Material and methods: This multicenter retrospective study included 2056 EC patients treated between 1994 and 2018 across 11 European centers. All histopathological subtypes and FIGO stages were included. Tumors were classified into four molecular subgroups: POLE-mutated (POLEmut), mismatch repair deficient (MMRd), no specific molecular profile (NSMP), and TP53/p53 abnormal (p53abn). Clinical and pathological data were extracted from existing cohort databases. Results: Patients were diagnosed with FIGO stage I (69 %), II (9 %), III (16 %), and IV (6 %), and classified into: POLEmut (8 %), MMRd (28 %), NSMP (44 %), and p53abn (21 %). The overall 5-year cancer-specific death (CSD) and recurrence rates were 16.5 % (95 % CI, 14.9 %-18.2 %) and 23.8 % (95 % CI, 22.0 %-25.7 %), respectively. In multivariable analysis cancer-specific survival (CSS) was independently associated with molecular subtype, FIGO stage, age, histopathological type, grade, lymphovascular space invasion, adjuvant therapy, residual tumor, and lymphadenectomy. FIGO stage was significantly associated with CSD also in within each molecular subgroup (p < 0.001). Patients with tumors confined to the uterus had the most favourable prognosis. Lymph node metastases significantly decreased CSS in POLEmut, MMRd, and p53abn groups. Within FIGO stage IV, molecular subtype was not significantly related to outcome. Discussion: Surgical stage remains a strong prognostic factor across molecular subtypes and should be considered alongside molecular classification when tailoring adjuvant treatment in EC.
ER  -

KASIUS, J. C.; W. KILDAL; S. W. VREDE; H. A. ASKAUTRUD; M. PRADHAN; A. M. VAN ALTENA; K.-A.R. TOBIN; K. KNOLL; C. REIJNEN; S. REIMANN; G. DACKUS; L. VLATKOVIC; J. HUVILA; M. STEINLECHNER; V. TUBITA; A. GIL-MORENO; M. P. L. M. SNIJDERS; M. C. VOS; T. S. HVEEM; J. ASBERGER; A. G. ZEIMET; X. MATIAS-GUIU; K. LINDEMANN; Vít WEINBERGER; N. C. M. VISSER; G. B. KRISTENSEN; F. AMANT; J. M. A. PIJNENBORG a A. KLEPPE. Surgical stage in the era of molecular profiling of endometrial cancer. \textit{European Journal of Cancer}. London: ELSEVIER, 2026, roč.~233, January 2026, s.~1-10. ISSN~0959-8049. Dostupné z: https://doi.org/10.1016/j.ejca.2025.116164.

Přehled o publikaci